Computational identification and in vitro evaluation of astragaloside II as an inhibitor of dengue virus NS1-induced endothelial hyperpermeability

Background Dengue is a mosquito-borne viral disease in which severe cases are marked by leakage of plasma from blood vessels. The secreted nonstructural protein 1 (NS1) of dengue virus damages the endothelial barrier and is a drug target, but no approved antiviral exists. We aimed to identify compounds that target NS1 and to test whether the selected compound, astragaloside II (ASII), counteracts NS1-induced endothelial hyperpermeability. Methodology/Principal findings We built a deep learning model that predicts compound–target binding from chemical fingerprints and protein sequences, and used it to prescreen 177 natural compounds against NS1 of the four dengue virus serotypes. The model outperformed the DeepConv-DTI baseline in recall and F1-score on a BindingDB holdout set and on two independent test sets. ASII was predicted to bind NS1 and was docked onto the NS1 dimer. In human microvascular endothelial cells (HMEC-1), NS1 reduced the relative trans-endothelial electrical resistance to 0.56 (P < 0.001), whereas ASII at 10–30 µg/mL kept resistance close to control levels without detectable cytotoxicity. ASII did not reduce NS1 internalization. In a competitive enzyme-linked immunosorbent assay, ASII inhibited NS1 binding to heparan sulfate in a dose-dependent manner (half-maximal inhibitory concentration 51.12 µg/mL; 95% confidence interval 47.91–56.24 µg/mL), although inhibition at the protective doses was only 8–26%. Conclusions/Significance ASII is a candidate for further study as a modulator of NS1-induced endothelial hyperpermeability. Its mechanism remains unresolved and requires further study. Direct binding to NS1, activity in infected cells and effects in other endothelial models were not tested here, and the computational predictions require experimental confirmation.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766166
Primary Topic
Mosquito-borne diseases and control
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Computational identification and in vitro evaluation of astragaloside II as an inhibitor of dengue virus NS1-induced endothelial hyperpermeability

Sarunya Maneerattanasak, Prasert Auewarakul, Sansanee Noisakran, Chanati Jantrachotechatchawan et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Mosquito-borne diseases and control
preprint

Computational identification and in vitro evaluation of astragaloside II as an inhibitor of dengue virus NS1-induced endothelial hyperpermeability

Sarunya Maneerattanasak, Prasert Auewarakul, Sansanee Noisakran, Chanati Jantrachotechatchawan, Panisadee Avirutnan, Pongpak Manoret, Chompunuch Boonarkart, Chunya Puttikhunt, Warun Maneepitasut, Kobchai Duangrattanalert, Natthawadee Leephatarakit, Wanida Chawnawa, Koravit Poysungnoen
preprint en

Abstract

Background Dengue is a mosquito-borne viral disease in which severe cases are marked by leakage of plasma from blood vessels. The secreted nonstructural protein 1 (NS1) of dengue virus damages the endothelial barrier and is a drug target, but no approved antiviral exists. We aimed to identify compounds that target NS1 and to test whether the selected compound, astragaloside II (ASII), counteracts NS1-induced endothelial hyperpermeability. Methodology/Principal findings We built a deep learning model that predicts compound–target binding from chemical fingerprints and protein sequences, and used it to prescreen 177 natural compounds against NS1 of the four dengue virus serotypes. The model outperformed the DeepConv-DTI baseline in recall and F1-score on a BindingDB holdout set and on two independent test sets. ASII was predicted to bind NS1 and was docked onto the NS1 dimer. In human microvascular endothelial cells (HMEC-1), NS1 reduced the relative trans-endothelial electrical resistance to 0.56 (P < 0.001), whereas ASII at 10–30 µg/mL kept resistance close to control levels without detectable cytotoxicity. ASII did not reduce NS1 internalization. In a competitive enzyme-linked immunosorbent assay, ASII inhibited NS1 binding to heparan sulfate in a dose-dependent manner (half-maximal inhibitory concentration 51.12 µg/mL; 95% confidence interval 47.91–56.24 µg/mL), although inhibition at the protective doses was only 8–26%. Conclusions/Significance ASII is a candidate for further study as a modulator of NS1-induced endothelial hyperpermeability. Its mechanism remains unresolved and requires further study. Direct binding to NS1, activity in infected cells and effects in other endothelial models were not tested here, and the computational predictions require experimental confirmation.

bioRxiv (Cold Spring Harbor Laboratory)
Siriraj Hospital (TH), Chulalongkorn University (TH), Duke University (US), Mahidol University (TH), TiGenix (Spain) (ES), National Centre for Genetic Resources and Biotechnology (NG), National Center for Biotechnology (KZ), National Institute of Genetic Engineering and Biotechnology (IR), National Center for Genetic Engineering and Biotechnology (TH)
Good health and well-being
Mosquito-borne diseases and control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon